Coloplast delivered 8% organic growth and EBIT increased by 12% to DKK 1,342m, corresponding to an EBIT margin of 30%, in the second quarter of the 2018/19 financial year. The company raises its expectations for reported growth in DKK from previously 8-9% to ~9% for 2018/19.

Coloplast delivered 8% organic growth in the second quarter. Year to date organic growth was also 8% and reported revenue in Danish kroner was up by 9% to DKK 8,722m. This is mainly due to a positive development in USD against DKK, and currency developments increased revenue by 1% in the second quarter.

In the second quarter, the organic growth rates by business area were 6% in Ostomy Care, 9% in Continence Care, 10% in Interventional Urology, and 9% in Wound & Skin Care.

Looking at sales by geography in the second quarter, the European markets contributed with 6% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 11% increase.

  • “We maintain solid growth rates across all geographical regions and business areas, and our organic revenue growth continues to be twice the market growth. I would like to highlight our strong performance in Europe driven by our product launches within Ostomy Care and Continence Care, SenSura® Mio Convex, SenSura® Mio Concave and SpeediCath® Flex, as well as our strong Wound Care performance driven by the Biatain® Silicone portfolio in Europe, particularly in the UK and France,” says CEO Kristian Villumsen, Coloplast. 

The incremental investments into innovation and sales and marketing initiatives of up to 2% of revenue that were initiated in Q1 are progressing according to plan.

EBIT amounted to DKK 2,639m for the first six months, a 10% increase in DKK, corresponding to an EBIT margin of 30% on par with the same period last year.

Important win in the US
Coloplast is the new primary ostomy supplier for Kindred at Home, a home health agency with more than 700 locations throughout 41 states. With an estimated market share of ~5%, Kindred at Home is the largest home health agency in the US.    

  • “The US market holds great potential for our company, and our ambition is to continue to take market share. Our aim is to deliver double digit growth in both Ostomy Care and Continence Care, while raising the standard of care and making sure patients have access to their preferred products. The contract with Kindred at Home is an important win for us,” says Mr Villumsen.

Financial guidance for 2018/19
Coloplast continues to expect organic revenue growth of ~8% at constant exchange rates and now a reported growth in DKK of ~9% from previously 8-9%.

Coloplast continues to expect an EBIT margin of 30%-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

Capital expenditure is now expected to be DKK ~700m from previously DKK ~750m, and we continue to expect the effective tax rate to be ~23%.

Lina Danstrup
Senior Media Relations Manager, Corporate Communications
+45 49 11 26 07

Ellen Bjurgert
Vice President, Investor Relations
+45 49 11 33 76

Financial highlights and key ratios (DKKm)2018/19
EBIT margin (in DKK)30%30% 
Profit for the period1,02191811%
Financial highlights and key ratios (DKKm)2018/19
EBIT margin (in DKK)30%30% 
Profit for the period2,0121,8588%

Sales performance by business area
Organic growthReported growth
Ostomy Care3,4783,2507%7%
Continence Care3,1632,8758%10%
Urology Care9638599%12%
Wound & Skin Care1,1181,00610%11%

Financial guidance

Guidance for 2018/19Guidance for 2018/19 (DKK)
Sales growth~8% (organic)~9% from previously 8-9%
EBIT margin30-31% (at constant exchange rates)~31%
Capital expenditure-~700 from previously ~750
Tax rate-~23%